We all have days on the job that we will always remember – milestones
that will become memories to cherish forever. I have served Novo
Nordisk for nearly 19 years in manufacturing facilities around the
world… and now I’ve just marked one of those memorable moments here –
in North Carolina where my family and I are now making our home. I
won’t soon forget it.
Marking the largest life science investment in North Carolina history, our company is committing $4.1 billion to build a state-of-the-art aseptic manufacturing and finished production facility in Clayton. Our goal? To increase our capacity to deliver more innovative medicines than ever before – and we chose to do it in a place Novo Nordisk has called home for more than three decades.
This investment marks one of Novo Nordisk’s largest manufacturing investments in the world. The expansion will add 1.4 million square feet of production space, effectively doubling the combined square footage of all three of our existing facilities in North Carolina’s Research Triangle region.
We already have more than 2,500 North Carolinians working at our sites. Now, this new investment will create 1,000 more new jobs in the community, furthering our footprint in what has become a central hub for innovation and biotechnology in the United States.
?wid=525&fit=constrain&qlt=90&$$)
Our new facility will utilize state-of-the-art technology, rooftop solar panels, and innovative water strategies. It is designed in an efficient and environmentally sustainable way to deliver the highest-quality products to patients around the world, further complementing our global sustainability goal of achieving zero environmental impact by 2045. Our eventual goal is to obtain LEED Gold certification, recognized as a standard of excellence in constructing healthy, efficient, and cost-saving green buildings.
The expansion of our facility reinforces our commitment to meeting the growing global need for our life-changing medicines. It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building on our ability to serve millions more people living with serious chronic diseases in the future.
Expected to be finalized between 2027 and 2029, this expansion is a testament of our commitment to driving change for our patients and making a difference in our communities. I’m excited to see what the future holds for this project and see our continued growth in this region I now call home.
